Concanavalin-A Shows Synergistic Cytotoxicity with Tamoxifen via Inducing Apoptosis in Estrogen Receptor-Positive Breast Cancer: In Vitro and Molecular Docking Studies

Mohamed F. Elshal1,*, Norhan M. Eid2, Ibrahim El-Sayed3, Wael El-Sayed4, Ahmed A. Al-Karmalawy4,5

1Department of Molecular Biology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City, Egypt.
2Chemistry Department, Faculty of Science, Kafrelsheikh University, Egypt.
3Genetics Department, Faculty of Agriculture, Beni-Suef University, Egypt.
4Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Hirus University-Egypt, New Damietta 34518, Egypt.

Abstract

Background: Tamoxifen (TAM) is the main treatment of estrogen receptor (ER)-positive breast cancer, however; its adverse effects and development of resistance hinder its use. Concanavalin A (Con A) is a mannose/glucose-binding lectin that has been reported to induce apoptosis in a variety of cell lines.

Methods: The effects of Con A on TAM-induced cell death in ERα positive cell line (MCF-7) were elucidated to identify the potential underlying molecular mechanisms using in silico (molecular docking) and in vitro (cytotoxicity assay, cell cycle analysis, annexin V-FITC apoptosis assay, and reverse transcription and quantitative real time-PCR) techniques as well.

Results: The results demonstrated that combined treatment with Con A and TAM reduced the expression of ERα, which showed clear synergistic effects on inhibiting the cell viability of MCF-7 cells. Interestingly, the combined treatment induces G1 phase arrest and reduces cyclin D1 activity while increasing apoptosis and autophagy as indicated by decreasing the expression level of anti-apoptosis gene BCl-2 and increased apoptosis/autophagic gene BNIP3. Molecular docking was conducted to evaluate the binding affinity of Con A towards ERα, and it revealed its potential activity as an ERα antagonist. Our data further indicated that Con A administration increased the drug reduction index of TAM.

Conclusion: Overall, our findings suggested that Con A could be used as an adjuvant agent with TAM to improve its effectiveness as an anticancer agent.

Introduction

Breast cancer (BC) is one of the most common malignant diseases and the leading cause of cancer-related death for women (2.09 million cases) worldwide.1 The disease occurs mostly in women, but men may get it as well.2 BC can invade the surrounding tissues or spread (metastasize) through the body to distant areas. BC is a heterogeneous disease comprised of several molecular subtypes, among which estrogen receptor-positive (ER+), i.e., expressing estrogen receptors endogenously is the most prominent type (about 75% of all patients). ERα is a transcription factor that regulates gene expression critical genes including cyclin D1, Bcl-2, and VEGF (Vascular endothelial growth factor), which play a significant role in the cell cycle, cell survival, and angiogenesis.3

Four major classes of pharmacological agents, referred to as endocrine therapy for ER+ breast cancer, are now available in the clinic. These include selective estrogen receptor modulators (SERMs), selective estrogen receptor down regulators (SERDs), aromatase inhibitors (AIs), and luteinizing hormone-releasing hormone analogs (LHRH analogs).4

Tamoxifen (TAM) is a selective estrogen receptor modulator that is currently considered the first-line treatment for ER+ BC in both pre-and post-menopausal women.5,6 TAM has also been introduced to be efficient in the prevention and treatment of ER+ breast tumors. It works as a selective estrogen receptor modulator (SERM) which combines with estrogen receptors in BC cells and stops their growth and multiplication by depriving them of the estrogen hormone.7 Besides, the toxicities of TAM, such as thromboembolic events and endometrial cancer, constitute a clinically significant issue, especially for their prevention. Moreover, nearly half of ER+ BC patients do not respond to TAM. However, the positive response is usually shortened as most patients develop TAM resistance.

*Corresponding Author: Ahmed A. Al-Karmalawy, E-mail:akarmalawy@horus.edu.eg & Mohamed F. Elshal, E-mail:Mohamed.Elshal@gebri.usc.edu.eg

©2021 The Author(s). This is an open access article and applies the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited.
within 2-5 years. Therefore, new strategies are needed to enhance the efficacy of TAM in the prevention and/or treatment of ER+ BC. One such strategy is to examine the efficacy of TAM in lower doses, along with another apoptotic compound that their combination is required to be related to lower toxicity.

Lectins from animal and plant origin are a family of proteins found in almost all foods, especially legumes and grains that induce apoptosis and autophagy of cancer cells and therefore possess the potential for the development of selective anticancer drugs. Concanavalin A (Con A) is a legume lectin that was long-studied and reported to have anticancer effects against diverse human cancers through targeted programmed cell death (PCD).

In continuation to our previous interesting work, we thought to investigate the potential of Con A to enhance the antitumor efficacy and reduce the adverse effects of TAM, and to deduce its molecular mechanism of action by in vitro and molecular docking studies.

**Materials and Methods**
Tamoxifen citrate salt, Con A, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), Dimethyl sulfoxide (DMSO), Annexin-V Staining Kit, RNAs-A, Propidium Iodide (PI), and triton x-100 were purchased from Sigma (United States). Dulbecco’s Modified Eagle’s Medium (DMEM), streptomycin, and Fetal Bovine Serum (FBS) was from GIBCO (Invitrogen Co., CA, USA).

**In vitro studies**

**Cell culture and treatment**
The in vitro cytotoxic activity of Con A and TAM against ER+ MCF-7 breast cancer cell line was measured using MTT assay as described in a previous study with some modifications. Briefly, MCF-7 cells were cultured at a concentration of 4x10^4 cells/cm² in DMEM medium containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C with 5% CO₂, 95% air, and complete humidity. Seeding density was determined manually by a hemocytometer using 0.4% trypan blue. At 40-50% confluency (48 hours post-seeding), the cultured cells were treated with either TAM or Con A alone at different concentrations (from 0.39 µM to 100µM) - which is a commonly used concentration range used to study the efficacy of the tested compound at different concentrations - for 24 h treated, and cells were left to grow for another 24 hours.

**Cytotoxicity assay**
Once cultured MCF-7 cells reached ~90% confluence, 50 µl of MTT (1mg/ml in PBS) was added to the culture medium, and cells were incubated at 37°C with 5% CO₂ for 3h. Next, the cells were washed and reincubated for an additional 5 min with 200 µl of DMSO. The optical density (OD) of the wells was determined using a plate reader at a test wavelength of 570 nm and a reference wavelength of 630 nm. The percentage of cell viability was calculated by (OD treated well – OD blank)/(OD untreated control – OD Blank) x 100. The percent of cytotoxicity equals 100 – cell viability %. The MTT assays were performed at least three times for each concentration to determine the half-maximal inhibitory concentration (IC₅₀) values of TAM and Con A.

**Combination index analysis**
The efficacy of the drug combination was tested according to the fixed ratio or ray design of the two drugs. In this study, efficacy was measured by percent inhibition of cancer cell proliferation for the two drugs individually, and in combination for a series of different concentrations (from 0.39 µM to 100µM) for 24 h. In the combination treatment, the concentration ratio of the two drugs is fixed. Dose-response data are the input data used to calculate the combination index (CI) by CompuSyn software version 1.0 (Ting Chao Chou and Nick Martin, Paramus, NJ, USA), which is based on the Chou–Talalay method to determine the nature of the interaction between the two-/three-agents. Based on CI values, the extent of synergism/antagonism may be determined. Whereas, CI < 1 refers to synergism; CI = 1 refers to an additive effect, and CI > 1 refers to antagonism. Besides, the drug reduction index (DRI) values above 1 indicate a preferred reduction in the dose of the drug combination compared to monotherapy.

**Cell cycle analysis**
Flow cytometry was used to detect both cell cycle phases and apoptosis in untreated or treated MCF-7 cell cutlers as previously discussed. Simply, MCF-7 BC cells were seeded at 8x10⁴, supplied with 5% CO₂, and incubated at 37°C overnight. The IC₅₀ of the three treatments (TAM, Con A, and combination) were applied to treat MCF-7 cells to record their effect on the cell population compared to the media (control). 48 h later, centrifugation of cell pellets for 5 min at 300g was done. After, cell pellets were fixed in 70% ethanol on ice for 15 min to be used for cell cycle analysis. The aforementioned pellets were treated with the staining solution of propidium iodide (PI) for 1 h at room temperature. Finally, the stained cells were preserved at 4°C in dark till their analysis through flow cytometry.

**Annexin V-FITC apoptosis assay**
FITC Annexin-V/PI kit was used to detect apoptosis according to the manufacturer’s protocol. Briefly, treated cells were washed using PBS, then a binding buffer (200 mL) was added containing Annexin V-FITC (5 mL) and PI solution (10 mL) for staining. After keeping at 25°C for 15 min., the flow cytometry analysis was applied to detect the apoptotic cells. This procedure was repeated triplicate and fluorescence-activated cell sorting (FACS) was used to analyze the samples.

**Reverse transcription and quantitative PCR**
The combining effects of Con-A on TAM mRNA expression for the target genes (ERα, Cyclin-D1, Bcl-2, and BNIP3)
Concanavalin-A as Anticancer

### Statistical analysis
Mean ± standard error of the mean (SEM) was applied to express the experimental results. Moreover, one-way ANOVA was used to analyze the obtained data, and a significant difference was considered by a p-value < 0.05.

### Results and Discussion
In vitro studies
TAM is the first-line treatment of ER+ breast tumors that inhibit cancer cell proliferation by antagonizing the transcription factor estrogen receptor. Unfortunately, 30–50 % of females with ER+ BC show primary or secondary resistance to TAM. De novo or intrinsic resistance to TAM appears in many cases resulting in tumor recurrence, progression, and metastasis. To overcome this critical problem, we tested the possibility of enhancing the efficacy of low doses of TAM by combining it with Con A, which has been demonstrated to have antiapoptotic and anticancer activities.

Con A enhances the cell proliferation inhibitory effects of TAM
MTT assay was performed to describe the antiproliferative effect of the combination of Con A and TAM, cell viability assays were performed in the ER+ MCF-7 BC cell line. Our data revealed that MCF-7 cells when incubated with different concentrations of Con A and TAM for 24 h, resulted in a more potent cellular proliferation inhibitory activity than TAM alone as indicated by the MTT reduction assay (Figure 1A). As the calculated IC$_{50}$ of Con A was 7.55 µM, and of TAM was 2.75 µM, while the combined Con A and TAM drug showed IC$_{50}$ of 0.9 µM, which indicates that it is more cytotoxic on cells than Con A or TAM alone (Figure 1B). These results are similar partly to Shi et al. study, who reported that Con A-induced dose- and time-dependent cell death in MCF-7. Those authors reported that the 15 µg/mL of Con A-induced inhibitory rate of MCF-7 cells reached nearly 50% (IC$_{50}$). The current data similarly indicated that Con A has a great cytotoxic effect on MCF-7 cells that may potentiate the antiproliferative effects of TAM.

To further describe and quantify the combination effects for two-drug either synergistic, antagonistic or additive; MCF-7 cells were exposed to Con A, TAM, or in combination (at a fixed ratio). The combination index (CI) curve clarified that the values of the CI were <1 at low and moderate fa values (IC$_{50}$-IC$_{80}$) which confirms the synergistic effect of Con A with TAM on MCF-7 cells (Figure 1C). The dose reduction index (DRI) represents a multiple of the dose reduction of the tested toxin combinations compared to each toxin at the same inhibition rate. The DRI curve showed that both Con A and TAM had a DRI value > 1 indicating an inhibitory effect. So, their combined treatment was better than each drug alone, suggesting that Con A could be advantageous to decrease the side effects of TAM in the combination therapy. Herein, the DRI for Con A is superior to that of

### Statistical analysis
Mean ± standard error of the mean (SEM) was applied to express the experimental results. Moreover, one-way ANOVA was used to analyze the obtained data, and a significant difference was considered by a p-value < 0.05.

### Results and Discussion
In vitro studies
TAM is the first-line treatment of ER+ breast tumors that inhibit cancer cell proliferation by antagonizing the transcription factor estrogen receptor. Unfortunately, 30–50 % of females with ER+ BC show primary or secondary resistance to TAM. De novo or intrinsic resistance to TAM appears in many cases resulting in tumor recurrence, progression, and metastasis. To overcome this critical problem, we tested the possibility of enhancing the efficacy of low doses of TAM by combining it with Con A, which has been demonstrated to have antiapoptotic and anticancer activities.

Con A enhances the cell proliferation inhibitory effects of TAM
MTT assay was performed to describe the antiproliferative effect of the combination of Con A and TAM, cell viability assays were performed in the ER+ MCF-7 BC cell line. Our data revealed that MCF-7 cells when incubated with different concentrations of Con A and TAM for 24 h, resulted in a more potent cellular proliferation inhibitory activity than TAM alone as indicated by the MTT reduction assay (Figure 1A). As the calculated IC$_{50}$ of Con A was 7.55 µM, and of TAM was 2.75 µM, while the combined Con A and TAM drug showed IC$_{50}$ of 0.9 µM, which indicates that it is more cytotoxic on cells than Con A or TAM alone (Figure 1B). These results are similar partly to Shi et al. study, who reported that Con A-induced dose- and time-dependent cell death in MCF-7. Those authors reported that the 15 µg/mL of Con A-induced inhibitory rate of MCF-7 cells reached nearly 50% (IC$_{50}$). The current data similarly indicated that Con A has a great cytotoxic effect on MCF-7 cells that may potentiate the antiproliferative effects of TAM.

To further describe and quantify the combination effects for two-drug either synergistic, antagonistic or additive; MCF-7 cells were exposed to Con A, TAM, or in combination (at a fixed ratio). The combination index (CI) curve clarified that the values of the CI were <1 at low and moderate fa values (IC$_{50}$-IC$_{80}$) which confirms the synergistic effect of Con A with TAM on MCF-7 cells (Figure 1C). The dose reduction index (DRI) represents a multiple of the dose reduction of the tested toxin combinations compared to each toxin at the same inhibition rate. The DRI curve showed that both Con A and TAM had a DRI value > 1 indicating an inhibitory effect. So, their combined treatment was better than each drug alone, suggesting that Con A could be advantageous to decrease the side effects of TAM in the combination therapy. Herein, the DRI for Con A is superior to that of

### Table 1. Primers sequences of the target genes (ER+, Cyclin-D1, Bcl-2, and BNIP3) and the housekeeping gene (GAPDH).

| Gene   | Primer sequence                      |
|--------|--------------------------------------|
| Era    | F 5′-GGTTACTGACACACTGCTGGCAGA-3′     |
|        | R 5′-GGTTACTGACACACTGCTGGCAGA-3′     |
| Bcl-2  | F 5′-GACTTCCGCCAGATGCTCCAG-3′        |
|        | R 5′-CAGTTGGCGGTTCAGGTACT-3′         |
| Cyclin D1 | F 5′-AGACCTGGGCGGCTCGGTTG-3′     |
|        | R 5′-ATGAGGCGGCAAGGAGTTTGC-3′       |
| BNIP3  | F 5′-CCACAAAAGGCAATGTCA-3′          |
|        | R 5′-AAGAGGGGCTTTGCCTACAAAT-3′      |
| GAPDH  | F 5′-GGCAATTCTCAACCGCGACAGT-3′      |
|        | R 5′-AGATGGGTATGGGCTTCCC-3′         |

were recorded using quantitative PCR. The housekeeping gene (GAPDH) in MCF-7 cells was done. Moreover, the primer sequences for the genes described in our study are depicted in Table 1. Herein, RNA from MCF-7 BC cells was obtained by many treatments for 48 h. The procedure was run at 95 ºC/30s, then 40 cycles of 95 ºC/5s, and 60 ºC/30s. 2 $-\Delta\Delta Ct$ method was used to analyze the obtained data as the average from the triplicate measurements.

Docking studies
Protein-protein docking for Con A and ERα was performed, and ERα was downloaded and prepared with its co-crystallized inhibitor, 4-Hydroxytamoxifen (4-OHT) molecules. Docking studies using MOE 2019 drug design suite were made free during minimization. The protein-protein docking of the aforementioned proteins was performed, where the prepared ERα protein was identified as the receptor, the lectin Con A protein was identified as the ligand, and the docking was started as a protein-protein docking process using hydrophobic patch potential. The connections of the atoms and the type, hydrogen atoms were prepared for docking studies using Quickprep where automatic correction was applied to check for any errors in the connections of the atoms and the type, hydrogen atoms with their standard 3D geometry were added, and all atoms were made free during minimization.

Protein-protein docking
The protocol of docking of the aforementioned proteins was applied, where the prepared ERα protein was identified as the receptor, the lectin Con A protein was identified as the ligand, and the docking was started as a protein-protein docking process using hydrophobic patch potential. The preplacement poses were (10000), the placement poses were (1000), and the refinement poses were (100). At the end of the docking process, the resulted 100 poses were carefully studied, and the best one with the best protein-protein interactions was selected and further studied for energy calculations.

### Statistical analysis
Mean ± standard error of the mean (SEM) was applied to express the experimental results. Moreover, one-way ANOVA was used to analyze the obtained data, and a significant difference was considered by a p-value < 0.05.

### Results and Discussion
In vitro studies
TAM is the first-line treatment of ER+ breast tumors that inhibit cancer cell proliferation by antagonizing the transcription factor estrogen receptor. Unfortunately, 30–50 % of females with ER+ BC show primary or secondary resistance to TAM. De novo or intrinsic resistance to TAM appears in many cases resulting in tumor recurrence, progression, and metastasis. To overcome this critical problem, we tested the possibility of enhancing the efficacy of low doses of TAM by combining it with Con A, which has been demonstrated to have antiapoptotic and anticancer activities.

Con A enhances the cell proliferation inhibitory effects of TAM
MTT assay was performed to describe the antiproliferative effect of the combination of Con A and TAM, cell viability assays were performed in the ER+ MCF-7 BC cell line. Our data revealed that MCF-7 cells when incubated with different concentrations of Con A and TAM for 24 h, resulted in a more potent cellular proliferation inhibitory activity than TAM alone as indicated by the MTT reduction assay (Figure 1A). As the calculated IC$_{50}$ of Con A was 7.55 µM, and of TAM was 2.75 µM, while the combined Con A and TAM drug showed IC$_{50}$ of 0.9 µM, which indicates that it is more cytotoxic on cells than Con A or TAM alone (Figure 1B). These results are similar partly to Shi et al. study, who reported that Con A-induced dose- and time-dependent cell death in MCF-7. Those authors reported that the 15 µg/mL of Con A-induced inhibitory rate of MCF-7 cells reached nearly 50% (IC$_{50}$). The current data similarly indicated that Con A has a great cytotoxic effect on MCF-7 cells that may potentiate the antiproliferative effects of TAM.

To further describe and quantify the combination effects for two-drug either synergistic, antagonistic or additive; MCF-7 cells were exposed to Con A, TAM, or in combination (at a fixed ratio). The combination index (CI) curve clarified that the values of the CI were <1 at low and moderate fa values (IC$_{50}$-IC$_{80}$) which confirms the synergistic effect of Con A with TAM on MCF-7 cells (Figure 1C). The dose reduction index (DRI) represents a multiple of the dose reduction of the tested toxin combinations compared to each toxin at the same inhibition rate. The DRI curve showed that both Con A and TAM had a DRI value > 1 indicating an inhibitory effect. So, their combined treatment was better than each drug alone, suggesting that Con A could be advantageous to decrease the side effects of TAM in the combination therapy. Herein, the DRI for Con A is superior to that of
TAM suggesting that its therapeutic combination with the latter could result in a TAM dose reduction and consequently reducing its side effects as well (Figure 1D).

**Con A synergizes with TAM in inducing G1 growth arrest**

The mainstream anticancer treatment induces cytotoxic effects and DNA damage leading to cell cycle arrest at G1, S, G2, and consequently preventing the replication of the damaged DNA which if not repaired, may cause tumorigenesis or apoptosis. Therefore, to investigate whether the aforementioned cytotoxic effects of the combined therapy might affect the cell cycle, MCF-7 cells treated with different concentrations of Con A and or TAM were analyzed using flow cytometry. Flow cytometry is a technique that measures many physical and biological characteristics that include a particle's size, internal complexity, or relative granularity and DNA content using the fluorescence intensity of certain DNA-intercalating fluorescent dyes such as Propidium Iodide. In the present study, the cell cycle assay of MCF-7 cells following different treatments showed altered cell cycle patterns compared to untreated controls (Figure 2).

The percentages of cells in G0/G1 were increased in all treatments, especially in the combined treatment of Con A/TAM, which showed a significant (P<0.05) increase compared with untreated MCF-7 cells. Treatment of cells with Con A and with TAM decreased the percent of cells in the S phase but not significantly compared to that of the control group (p > 0.05). Cells treated with Con A and with TAM showed a significant (p < 0.05) decrease in the G2/M phase (3.53% and 4.12% respectively) in comparison to that of the control group (12.79%). Besides, the combined treatment, Con A/TAM showed significantly (p < 0.05) decreased G2/M compared with control untreated MCF-7 cells (Figures 2A, B). These results indicate that Con A synergistically with TAM could inhibit the growth of ER+ MCF-7 cancer cells by arresting the cell cycle at G1.

**Con A enhances the apoptotic effects of TAM**

Besides cell cycle blockage at the G0/G1 phase of cell progression, another mechanism called apoptosis may be implicated in the cytotoxic effects of TAM and Con A on MCF-7 cell lines. Previous studies indicated that apoptosis is related to cell cycle arrest, whereas the compounds which can induce cell cycle arrest and apoptosis are considered to have anticancer potential. The rates of cell apoptosis were evaluated in the present study by two different methods, the pre-G1 phase of the DNA-cell cycle and by Annexin-V/PI dual staining assays using flow cytometry. The percentages of apoptotic cells in pre-G1 were found to increase significantly from 1.17 ± 0.39 % for the control group to 29.91 ± 1.89 %, 33.4 ± 1.89 %, 44.9 ± 1.89 %, following exposure to Con A, TAM, and their combination, respectively (Figure 2C).

Also, Annexin V apoptosis assay revealed that, while most cells in the control group were negative to both Annexin V-FITC and PI stains, cells treated with Con-A, TAM or their combination showed significant increases in the ratios of both early and late apoptosis cells, while the percentage of the viable cells was decreased (Figure 3A). Meanwhile, the necrotic cell population was also slightly increased (Figure 3B). Our study has shown that treatment
Concanavalin-A as Anticancer

Figure 2. Impact of Con A and/or TAM on the cell cycle phases of MCF-7 cells. A) Representative DNA-cytograms of the different treatments as determined by flow cytometry. B) The cell cycle phases. C) Apoptotic cells as determined by the pre-G1 phase of the cell cycle. The values indicate the mean ± SD of the three experiments. *, ** Significantly different compared to the untreated control cells at p-value < 0.05, and < 0.01 respectively.

of ER\(^+\) MCF-7 cells with Con-A induced inhibition of cell proliferation by increased cell apoptosis, and augmented the antiproliferative properties of TAM, suggesting that Con-A could be a promising drug for cancer treatment. These data are in line with previous studies that reported the ability of Con-A to induce apoptosis in certain types of tumors.\(^{10,11}\)

Molecular mechanism of the G1 arrest and apoptosis induced by Con A and TAM
ER\(\alpha\) is a key transcription factor in breast cancer that participates in a variety of different signaling pathways. It promotes the expression of the oncogenic protein cyclin D1 that regulates cell proliferation through its regulation of G1-S cell cycle progression.\(^34\) Also, it was reported that downregulation of ER\(\alpha\) accompanied by retardation of the S-phase, and reducing the expression of cyclin D1, consequently leading to G1 arrest.\(^35\) In agreement with the abovementioned data, we found that the inhibition of MCF-7 cell growth was accompanied by the downregulation of ER\(\alpha\) mRNA that was treated with Con A (0.73-fold), TAM (0.55-fold), and a combination of Con A and TAM (0.37-fold) (Figure 4A).

Besides, the levels of Cyclin D1 mRNA were downregulated significantly posttreatment with combined Con A and TAM more than either treatment alone (Figure 4B). These data confirm the previous finding that blocking ER\(\alpha\) induces cell cycle arrest at G1 through downregulating cyclin D1.\(^36\) Moreover, Katary \textit{et al}.\(^37\) have reported that mechanisms linking the reduction of the oncogenic protein cyclin D1 correlate with a reduction in the cellular component of anti-apoptotic molecules NF-κB, Bcl-2 proteins leading to induction of apoptosis. Thereby, emphasizing the role of Bcl-2 in inducing apoptosis in ER\(^+\) MCF-7 cells. Bcl-2 is an anti-apoptotic protein that inhibits apoptosis either by sequestering the apoptosome assembly of caspases or by preventing the release of cytochrome c and AIF (apoptosis-inducing factor).\(^38\) In the present study, it was found that Bcl-2 gene expression was decreased (0.3-fold) compared to the control following treatment of MCF-7 BC cells with Con A (Figure 4C). Furthermore, the cells treated with combined Con A/TAM showed an enhanced reduction in Bcl-2 expression than either monotherapy alone. Data from these experiments suggest that Con A may act as an apoptosis inducer that works synergically with TAM in decreasing the expression of Bcl-2 in ER\(^+\) BC cells with Con A (Figure 4C). Furthermore, the cells
Figure 3. The effects of Con A, TAM, or combination Con A/TAM on the rate of apoptosis in MCF-7 cells. (A) Representative cytogram of cells stained with AnnexinV-FITC/PI. (B) Distribution of apoptotic cells after the different treatments. The values represent the mean ± SD (n = 2). * and **, significantly different compared to the untreated control cells at p-value < 0.05, and < 0.01, respectively.

Figure 4. The effect of treating ER+ MCF-7 cell lines with Con A and/or TAM on the relative expression of ERα (A), Cyclin D1 (B), BCl-2 (C), and BNIP3 (D). The values represent the mean ± SD (n = 2). * * Significantly different from corresponding untreated control cells at p-value < 0.05 and < 0.01, respectively.

treated with combined Con A/TAM showed an enhanced reduction in Bcl-2 expression than either monotherapy alone. Data from these experiments suggest that Con A may act as an apoptosis inducer that works synergically with TAM in decreasing the expression of Bcl-2 in ER+ human BC.

Con A enhances the autophagic effects of TAM

On the other hand, BNIP3 (BCI-2/adenovirus E1B 19 kDa interacting protein) is a pro-apoptosis protein regulated by the methylation status of its promoter, which has been implicated in inducing necrosis, autophagy, and/or apoptosis.39 It has been shown that BNIP3 expression is increased in hypoxic regions of breast tumors.40 Autophagy refers to an evolutionary conserved process for maintaining homeostasis and eliminating harmful cells.32 It was reported that Con A can inhibit cancer cell growth through binding to mannose glycoproteins and is proposed to make an autophagic pathway in hepatoma ML-1 cells.37 This is indicated by the formation of LC3-II which is an autophagy marker, and induction of BNIP3 which is a protein associated with autophagy; suggesting Con A can induce mitochondrial apoptosis and BNIP3-mediated mitochondrial autophagy, and therefore causing cancer cell death.40 In the present work (Figure 4D), treatment with Con A and TAM drugs stimulated the overexpression of BNIP3 protein (3.48-fold), TAM (4.32-fold), and combination with both (7.53-fold) compared to the control cells (1-fold), suggesting that combined treatment of MCF-7 cells with Con A and TAM drug stimulate BNIP3-induced autophagic cell death.

Molecular docking studies

Molecular docking is an approach used to model the
interaction between certain molecules and a protein at the cellular level that allows the researcher to study the interactions of small molecules inside the binding pocket of target receptors and to explain the predicted mechanisms of action as well.\textsuperscript{41-44} Therefore, molecular docking analysis was conducted to investigate whether the induction of apoptosis, autophagy, and G1 blockade by Con A was due to interaction with cells' ERα. By analyzing the protein-ligand interaction fingerprints (PLIF), it was found that Leu A308, Thr C334, Val A368, Thr A371 were the most important amino acids in ERα protein involved in the interaction with lectin protein (Figure 5).

At the same time, the most observed interaction between lectin and ERα was recorded for pose 15 with a binding score of -44.76 kcal/mol and rmsd_refine value of 2.49. Pose 15 showed a very large area of interaction between lectin and ERα protein, proposing greatly the promising antagonistic effect of Con A on the ERα and its expected synergistic effect with TAM in suppressing the ERα as well (Figures 6 and 7).

**Conclusion**

In summary, the combination of Con A and TAM showed synergistic antiproliferative, and apoptotic effects, which were approved through in vitro studies using MTT assay, cell cycle analysis, and Annexin V-PI apoptosis assay. The proposed mechanisms of the aforementioned effects were downregulation of the ERα mRNA that was accompanied by the downregulation of cyclin D1, which regulates the G1 phase cell cycle and the antiapoptotic gene Bcl-2. Meanwhile, the Con A/TAM combination is accompanied by a significant increase in the expression of the proapoptotic/autophagic gene BNIP3. Furthermore, docking studies suggested that Con A antagonizes greatly the ERα. These findings may explain the potential synergistic antitumor activity of Con A/TAM combination.
on ERα MCF-7 BC cells. This synergistic action of the Con A/TAM combination is proposed to be through achieving two crucial outcomes. First, reducing the therapeutic dose of TAM as indicated by DRI and hence decreases its side effects which hinder its use in many cases. Second, it will decrease the recently prominent chemo-resistance of cancerous cells to TAM through blocking ERα. Therefore, we suggest that Con A in combination with TAM is a new potential strategy for treating the ERα positive subtype of breast cancer.

**Author Contributions**

MFE: Conception and design of the work, acquisition, analysis, interpretation of data for the work, and drafting the work. NME: Analysis and interpretation of data for the work. IE: Analysis and interpretation of data for the work. WE: Drafting the work. AAA: Analysis and interpretation of data for the work, drafting the work, and revising it. All authors read and approved the final manuscript.

**Conflict of Interest**

The authors report no conflicts of interest.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492

2. Girish C, Vijayalakshmi P, Mentham R, Rao CB, Nama S. A review on breast cancer. Int J Pharma Bio Sci. 2014;4(2):47-54.

3. Dall GV, Britt KL. Estrogen effects on the mammary gland in early and late life and breast cancer risk. Front Oncol. 2017;7:110. doi:10.3389/fonc.2017.00110.eCollection 2017.

4. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2.

5. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305(1):1-6. doi:10.1056/NEJM198107023050101

6. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International breast cancer study group trial 13-93. J Clin Oncol. 2006;24(9):1332-41. doi:10.1200/JCO.2005.03.0783

7. Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, et al. Oral low dose and topical tamoxifen for breast cancer prevention: Modern approaches for an old drug. Breast Cancer Res. 2012;14(5):214. doi:10.1186/bcr3233

8. Sweeney EE, McDaniel RE, Maximov PY, Fan P, Jordan VC. Models and mechanisms of acquired anti-hormone resistance in breast cancer: Significant clinical progress despite limitations. Horm Mol Biol Clin Investig. 2012;9(2):143-63. doi:10.1515/hmbci-2011-0004

9. Fox JL, MacFarlane M. Targeting cell death signalling in cancer: Minimising ‘collateral damage’. Br J Cancer. 2016;115(1):5-11. doi:10.1038/bjc.2016.111

10. Yau T, Dan X, Ng CCW, Ng TB. Lectins with potential for anti-cancer therapy. Molecules. 2015;20(3):3791-810. doi:10.3390/molecules20033791.

11. Li W-w, Yu J-y, Xu H-l, Bao J-k. Concanavalin a: A potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. Biochem Biophys Res Commun. 2011;414(2):282-6. doi:10.1016/j.bbrc.2011.09.072

12. Shi Z, Chen J, Li C-y, An N, Wang Z-j, Yang S-l, et al. Antitumor effects of concanavalin a and sophora flavescentis lectin in vitro and in vivo. Acta Pharmacol Sin. 2014;35(2):248-56. doi: 10.1038/aps.2013.151

13. Al-Karmalawy AA, Khattab M. Molecular model-
Concanavalin-A as Anticancer

Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergy and antagonism in drug combination studies. Pharm Rev. 2006;58(3):621-81. doi:10.1124/pr.58.3.10.

Osman A-MM, Bayoumi HM, Al-Harthi SE, Damanhouri ZA, ElShal MF. Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int. 2012;12(1):47. doi:10.1186/1475-2867-12-47

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. doi:10.1006/meth.2001.1262

Inc. CCG. Molecular operating environment (MOE). Chemical Computing Group Inc 1010 Sherbooke St. West, Suite# 910, Montreal; 2016.

Heldring N, Pawson T, McDonnell D, Treuter E, Gustafsson J-A, Pike ACW. Structural insights into corepressor recognition by antagonist-bound estrogen receptors. J Biol Chem. 2007;282(14):10449-55. doi:10.1074/jbc.M611424200

Gierach GL, Curtis RE, Pfeiffer RM, Moolooly M, Ntowe EA, Hoover RN, et al. Association of adjuvant tamoxifen and aromatase inhibitor therapy with contralateral breast cancer risk among US women with breast cancer in a general community setting. JAMA Oncol. 2017;3(2):186-93. doi:10.1001/jamaoncol.2016.3340

Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer. 1994;57(6):847-55. doi:10.1002/ijc.2910570614

Darzynkiewicz Z, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Seminars in hematology. 2001; Amsterdam: Elsevier.

Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487-98. doi: 10.1111/j.1365-2184.2012.00845.x

Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: Mechanisms and relevance in cancer. Ann Hematol. 2005;84(10):627-39. doi:10.1007/s00277-005-1065-x

Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin d1 promoter: Involvement of a camp response-like element. Proc Natl Acad Sci U S A. 1999;96(20):11217-22. doi:10.1073/pnas.96.20.11217

Petrizzi VB, Cicatiello L, Altucci L, Addeo R, Borgo R, Cancemi M, et al. Transcriptional control of cell cycle progression by estrogenic hormones: Regulation of human cyclin d1 gene promoter activity by estrogen receptor-a. In: Li JJ, Li SA, Daling JR. Editors. Hormonal carcinogenesis iii: Proceedings of the Third International Symposium. New York: Springer; 2001. p. 206-19

Lamb R, Lehn S, Rogerson L, Clarke RB, Landberg G. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in...
37. Katary MA, Abdelsayed R, Alhashim A, Abdelhasib M, Elmarakby AA. Salvianolic acid B slows the progression of breast cancer cell growth via enhancement of apoptosis and reduction of oxidative stress, inflammation, and angiogenesis. Int J Mol Sci. 2019;20(22):5653. doi:10.3390/ijms20225653.

38. Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: Apoptosomes or mitochondria? Genes Cells. 1998;3(11):697-707. doi:10.1046/j.1365-2443.1998.00223.x

39. Burton TR, Gibson SB. The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ. 2009;16(4):515-23. doi:10.1038/cdd.2008.185

40. Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ. 2009;16(7):939-46. doi:10.1038/cdd.2009.16

41. McConkey BJ, Sobolev V, Edelman M. The performance of current methods in ligand–protein docking. Curr Sci. 2002;83(7):845-56.

42. Al-Karmalawy AA, Alnajjar R, Dahab M, Metwaly A, Eissa I. Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit covid-19 main protease. Pharm Sci. 2021;27(Suppl 1):S109-S21. doi:10.34172/PS.2021.3

43. Elmaaty AA, Alnajjar R, Hamed MI, Khattab M, Khalifa MM, Al-Karmalawy AA. Revisiting activity of some glucocorticoids as a potential inhibitor of sars-cov-2 main protease: theoretical study. RSC Adv. 2021;11(17):10027-42. doi:10.1039/D0RA10674G

44. Alnajjar R, Mostafa A, Kandeil A, Al-Karmalawy AA. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin ii receptor blockers to inhibit the covid-19 main protease. Heliyon. 2020;6(12):e05641.